Probing the Probes: Fitness Factors For Small Molecule Tools  by Workman, Paul & Collins, Ian
Chemistry & Biology
PerspectiveProbing the Probes: Fitness Factors
For Small Molecule ToolsPaul Workman1,* and Ian Collins2,*
1Signal Transduction and Molecular Pharmacology Team
2Medicinal Chemistry Team
Cancer Research UKCentre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, SM2 5NG, UK
*Correspondence: paul.workman@icr.ac.uk (P.W.), ian.collins@icr.ac.uk (I.C.)
DOI 10.1016/j.chembiol.2010.05.013
Chemical probes for interrogating biological processes are of considerable current interest. Cell permeable
small molecule tools have a major role in facilitating the functional annotation of the human genome, under-
standing both physiological and pathological processes, and validating new molecular targets. To be
valuable, chemical tools must satisfy necessary criteria and recent publications have suggested objective
guidelines for what makes a useful chemical probe. Although recognizing that such guidelines may be valu-
able, we caution against overly restrictive rules that may stifle innovation in favor of a ‘‘fit-for-purpose’’
approach. Reviewing the literature and providing examples from the cancer field, we recommend a series
of ‘‘fitness factors’’ to be considered when assessing chemical probes. We hope this will encourage innova-
tive chemical biology researchwhileminimizing the generation of poor quality andmisleading biological data,
thus increasing understanding of the particular biological area, to the benefit of basic research and drug
discovery.
Open access under CC BY-NC-ND license.Introduction: Why Probe the Probes?
Understanding Genomes, Normal Biology,
and Disease Pathology
The publication of the human genome sequence was a land-
mark in biological research (Lander et al., 2001; Venter et al.,
2001; www.ornl.gov/sci/techresources/Human_Genome/home.
shtml). It provides the basis for understanding the role of all
genes in normal physiology and disease pathology, particularly
when coupled to the sequencing of the genomes of cancer
cells (Stratton et al., 2009) as well as infectious organisms
(Berriman et al., 2009) and other species (www.ensembl.org/
info/about/species.html). Chemical tools are playing an
important role, alongside molecular biology and genetic tech-
niques, in functional annotation of the human genome (http://
nihroadmap.nih.gov/molecularlibraries/index.asp; Austin et al.,
2004) and in expanding the druggable genome (Hopkins and
Groom, 2002; Overington et al., 2006). An ambitious and
inspiring early grand challenge that was set for the emerging
fields of chemical genetics and chemical biology was to identify
small molecule probes for the products of all human genes
(Schreiber, 1998).
The discovery and exploitation of chemical probes has
evolved from the more traditional ad hoc pharmacological
approach—where advantage was taken of individual natural
products and drugs to explore cellular processes—to the current
higher throughput approaches that are now in widespread use in
both academia and industry (Austin et al., 2004; Frearson and
Collie, 2009) and that facilitate interrogation of chemical and
biological space in a more systematic way (Schreiber, 2003;
Dobson, 2004). Although terms such as molecular pharma-
cology, chemical genetics, and chemical biology can be useful
to indicate nuances of approach, the overall unifying principle
is the use of small molecules to understand the function of genes
and proteins and their role in physiology and pathology.Chemistry & BiSynergies between Chemical Biology and Drug
Discovery: Good Probes Are Key
There are major synergies betweenmore basic chemical biology
research and drug discovery (Anonymous, 2009). From a drug
discovery perspective, chemical probes are key players in
validating new molecular targets for therapeutic exploitation
and in providing proof of concept for potential druggability of
a molecular target, pathway, or process by small molecules.
They can help to minimize the technical and biological risk for
a biological target or pathway of interest. Chemical tools can
also serve as pathfinder molecules in drug discovery projects,
informing the design and evaluation of biological assay cas-
cades and the identification of useful biomarkers.
Importantly, chemical probes are highly complementary to
the use of RNA interference (RNAi), in particular in being able
to inhibit a specific function of the target protein rather than
removing the whole protein, thus avoiding multiple function or
scaffold effect issues; in giving an immediate inhibition rather
than a delayed knockdown; and in providing greater control
over the extent and kinetics of inhibition (Weiss et al., 2007).
Both chemical probes and the use of RNAi can have off-target
as well as on-target effects. Use of these approaches in parallel,
as well asmakingmutated alleles of target proteins (Bishop et al.,
2000), can give us much greater confidence in functional anno-
tation and target validation.
Over a longanddistinguishedhistory, theuseof smallmolecule
chemical tools has led to advances in biological understanding
and therapy in such diverse areas as the cytoskeleton (colchi-
cine, palitaxel), mitosis (monastrol), immunophilins and immuno-
suppression (FK506, cyclosporin), mTOR (rapamycin), histone
deacetylases (trapoxin, vorinostat), protein kinases (phorbol
esters, staurosporine, tyrphostins, and many others), PPARg
(thiazolidinediones, 2-chloro-5-nitrobenzanilide GW9662), and
very recently, stem cell reprogramming (Emre et al., 2007).ology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 561
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From the examples cited above and others, it seems that the use
of chemical probes has been extremely effective and is having
a growing impact as a result of powerful new technologies.
Chemical probes are clearly helping basic research and drug
discovery. So why do we need rules or guidelines introduced
into what seems to be a productive process? If it ain’t broke
why try to fix it?
Few would dispute that to be valuable in chemical biology and
drug discovery research, chemical tools must satisfy at least
some basic criteria, such as permeability (getting to the site of
action in the cell), potency (inhibiting the target at reasonable
concentrations) and selectivity (not being unacceptably promis-
cuous). The principle of ‘‘garbage in, garbage out’’ applies here
big time. If a biologist uses a lousy probe, then the interpretation
of biological results will likely be flawed.
Recent publications have suggested objective guidelines for
what makes a useful chemical probe for application in biological
research (Oprea et al., 2007; Cohen, 2009; Edwards et al., 2009;
Frye, 2010; Kodadek, 2010). The emergence of guidance for
probes is analogous to guidelines (sometimes referred to as
rules, although they are more ‘‘rules of thumb’’) that have proved
to be of real practical value for assessing the suitability of frag-
ment or high-throughput screening (HTS) pharmaceutical leads
for progression to drug candidates, and also for judging the
candidates themselves (Lipinski et al., 2001; Oprea et al., 2001;
Rees et al., 2004; Davis et al., 2005; Collins andWorkman, 2006).
The potential need for guidelines for probes has been stimu-
lated recently by the increase in public screening efforts and in
particular, the assessment of the output of the large National
Institute of Health Molecular Library and Imaging Initiative (NIH
MLI) (http://nihroadmap.nih.gov/molecularlibraries/index.asp;
Austin et al., 2004). In a high profile expert ‘‘crowdsourcing’’
review (Oprea et al., 2009) of the burgeoning output of the pilot
phase of the NIH MLI that ran from 2004 to 2008 at an estimated
cost of US $385 million, a significant proportion (25%) of the
64 chemical probes generated were considered to have a high
‘‘dubiosity’’ rating, with low confidence in their value as probes,
whereas 25% and 50% were viewed as inspiring medium- and
high-confidence, respectively. A recent conference presentation
(Bologna, 2010) identified concerns with a high proportion of
the NIH MLI hits and noted the very low citation rate for most
NIH MLI probes proposed to date. Criteria for the nomination
of a chemical probe were made more stringent during the pilot
phase. Especially given the increasing involvement in the
production and use of probes of scientists who may have less
experience in this area than pharmaceutical industry profes-
sionals, the development of guidance for assessing potential
probes does seem appropriate (see Kaiser [2008]).
On the other hand, nobody–and not just the more anarchic or
rebellious fringe–wants a chemical biology thought police that
dictates overly prescriptive rules that stifle innovation (Hoffmann
and Bishop, 2010). Rules are unlikely to work. Moreover, as we
will discuss later, probes evolve with time and need to be given
a chance to be improved, especially in new research areas.
A balance needs to be struck between allowing freedom for
creativity and establishing sensible guidelines that eliminate at
least the worst offenders among flawed probes and that
encourage good practice in the community.562 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigFinding the Balance and Examples from Oncology
Against the above background, we discuss the recently emerg-
ing views concerning the desirable properties of chemical
probes. After reviewing proposed guidelines and offering our
own recommendations, we will illustrate these with several
case histories of biological targets that have benefited particu-
larly well from the use of progressively enhanced chemical
probes. The selection of these cases is made from the cancer
therapeutic area because, with outcomes from the human
genome sequence now being reviewed 10 years on from the
initial announcement, cancer is seen clearly to be the area that
has benefitedmost in terms of the discovery and implementation
of personalized, genome-based medicines (Collins, 2010;
Golub, 2010). Chemical probes have contributed considerably
to the progress made with targeted cancer therapies and many
of the drugs or analogs thereof have, in turn, served as small
molecule tools for use in the lab. Note, however, that although
the illustrative examples are taken from oncology, the views
expressed on chemical probes should be of generic relevance
across basic, translational and drug discovery research.
We advocate a ‘‘fit-for-purpose’’ approach to the properties of
chemical probes, recommending ‘‘fitness factors’’ for probe
evaluation. When combined with rigorous ongoing characteriza-
tion and transparent reporting of the advantages and limitations
of chemical probes together with open availability of reagents
and data, a flexible, evidence-based strategy that is geared to
the current understanding of the particular biological area should
encourage innovative chemical biology research while mini-
mizing the generation of poor quality and misleading biological
data. Progressive characterization and iterative refinement of
chemical tools by the international scientific community can
then follow in parallel with increased comprehension of the
particular biological area, to the benefit of basic and translational
research and drug discovery.
Emerging Guidelines for Probes
In this section, we discuss recent proposals for the preferred
properties of tool compounds and recommend what we term
‘‘fitness factors’’ for fit-for-purpose chemical probes. We build
on previous guidelines that have been put forward for deter-
mining the use of chemical probes and the confidence in results
derived from them (e.g., see Cohen, 2009; Frye, 2010; Kodadek,
2010 and references in the legend to Figure 1). Cohen and
colleagues have particularly focused on choosing high quality
protein kinase inhibitors for interrogating targets in cells, where
selectivity of the agents is paramount (Cohen, 2009; Davies
et al., 2000; Bain et al., 2003; Bain et al., 2007). Recognizing
the challenge of specificity given the more than 500 protein
kinases in the human genome, in his recommendations, entitled
‘‘guidelines’’, Cohen (2009) describes essential and desirable
‘‘criteria’’ for kinase probes. Frye (2010) was careful to draw
a distinction between rules, which he argued were unrealistic
in view of the numbers of parameters involved, in contrast to
the more practical use of a small number of relatively simple
‘‘principles’’ or guidelines that could be of great value. These
principles covered the biological and physicochemical proper-
ties needed in chemical probes that are intended for use in es-
tablishing the broader biological consequences of modulating
a molecular target.hts reserved
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promiscuous compounds identified from HTS assays (Baell
and Holloway, 2010; Inglese et al., 2007), especially in avoiding
unspecific chemical reactivity (Rishton, 2003) and aggregation
due to poor aqueous solubility (McGovern et al., 2003). Avoid-
ing these undesirable properties will reduce the risk of a
chemical probe exhibiting nonspecific effects. The importance
of emphasizing these issues, which are well known in the phar-
maceutical industry, is illustrated by the fact that significant
problems with these properties were identified in the recent
assessment of NIH MLI probes (Oprea et al., 2009; Bologna,
2010).
Specific guidelines for probes from the NIH MLI program
are available (Lazo et al., 2007; Oprea et al., 2007;
http://mli.nih.gov/mli/wp-content/uploads/probe-guidelines-v2-
accepted-by-sc-200707.doc). It is interesting that in the
recent crowdsourcing analysis of NIH MLI probes there was
a fascinating divergence of views on individual putative
probes among the various expert panel members (see
Supplementary Material in Oprea et al., 2009). Thus there
will be an important element of judgment based on experi-
ence involved in the assessment of probes, even with guide-
lines available.C
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Figure 1. (continued).
Chemistry & BiFitness Factors for Chemical Probes
The various existing guidelines mentioned above are interpreted
and augmented with our own suggestions for fitness factors in
Figure 1. We define these fitness factors as the key properties
of chemical probes that should be evaluated in relation to their
intended use to give confidence that they are fit-for-purpose.
The performance of a probe with respect to the separate fitness
factors taken together provides an assessment of the suitability
of a given probe and of potential uncertainties in interpreting
biological data obtained with it.
Figure 1 highlights the four main categories into which the
fitness factors are classified. Collectively these define the suit-
ability of a given chemical probe for exploratory biology. The
four main categories are: (1) chemical properties, (2) biological
potency, (3) biological selectivity, and (4) context of use. The
fitness factors within each class are discussed in detail below.
We also raise questions of experimental use that are important
to consider in assessing the quality of chemical probes.Whereas
the fitness factors are expressed for convenience as a ‘‘check-
list’’ and commonly discussed threshold values are presented
in Table 1, we do not imply that a rigid adherence to fixed values
is always appropriate. Rather, they are criteria that may be used
to facilitate judgments of the robustness of data generated withS
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Chemistry
Structure Discrete chemical species, characterised spectroscopically;
Defined structure with reproducible preparative method
Stability Defined purity and stability in test media;
Free from non-specific chemical reactivity
Solubility Sufficiently soluble in aqueous media; e.g. >100 µM;
No aggregation effects in biochemical assays
Permeability Proven passive membrane permeability, or defined active transport
mechanisms
Potency
Biochemical Typically <100 nM in an in vitro biochemical assay;
Sufficient to confidently associate with cellular activity
Cellular Typically <1-10 µM in a mechanistic cell-based assay;
Sufficient to confidently address hypotheses in cells;
Concentration-dependent effect on the biological target
Analogs Closely related structures identified with similar activity;
Correlation of biochemical target activity and activity in cells;
Correlation of biomarkers of target modulation with biochemical and
cellular potency
In vivo Pharmacokinetic properties sufficient to achieve levels in target tissue
relevant to cellular potency
Selectivity
Profile Defined selectivity for related targets or known targets of chemotype;
Typically >10-100 fold in biochemical assay; typically >50 kinases
profiled for kinase inhibitors; broader pharmacology profiling desirable
Inactive analog Analog with no biochemical target activity shows no activity in cells
Other chemotypes Probes from a different chemical class with similar activity
Chemoinformatics Awareness of other activities associated with the chemical class
Context
Genetic methods RNAi and/or mutants of target available for complimentary experiments
Target Cellular context of the target and potential linked activities considered
Application Fitness of the probe to test the specific biological hypothesis considered
Availability Origin, identity and properties fully disclosed;
Available for use without restrictions;
Accessible in quantities (15-20 mg) for follow-up studies
B
Figure 1. Fitness Factors for Chemical Probes Grouped into Four Distinct Areas
Chemical properties, biological potency, biological selectivity, and context of use (A), that encompass suggested criteria for evaluating the suitability of chemical
probe compounds for exploratory biology (see Baell and Holloway, 2010; Cohen, 2009; Edwards et al., 2009; Frye, 2010; Inglese et al., 2007; Kodadek, 2010;
McGovern et al., 2003; Oprea et al., 2007; Rishton, 2003). Threshold values that have been suggested in the literature are tabulated for each of the criteria (B), and
a comparison of these properties for drugs, leads, and probes can be found in Table 1. We suggest that although not all probes can, or need to, reach these
thresholds in every case, consideration of the criteria will allow a robust assessment of whether the probe is fit-for-purpose, and foster an appreciation of the
risk carried forward if significant criteria are not met.
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Perspectiveparticular probes in particular settings, and are intended to help
estimate the risks that may be carried forward in building on
data generated from the use of new chemical probes where, of
necessity, incomplete characterization is available. Importantly,
expertise in both chemistry and biology must be applied in this
process.564 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigThe Big Four
Chemistry. The need for well-characterized chemical identity
and purity of chemical probes is clear cut. It is also important
that reliable and reproducible procedures for the synthesis
of the compounds are available. The chemical stability of the
compounds in relevant media should be evaluated, particularlyhts reserved
Table 1. Calculated and Experimental Properties of Drugs, Leads, and Probes
DrugsA,Co,G,O,L1,L2,W,Wo LeadsCo,K,L1,L2,O,Wo ProbesC,E,F, Ko,O
Aqueous solubility >10–100 mg/ml >10–100 mg/ml >0.05 mg/ml in low % DMSO
aqueous solutions
Membrane permeability 103 permeability of mannitol in
CaCo-2 assay desirable; minimal
PGP-mediated efflux
Pe > 10
6 ms1 (in vitro assay);
minimal PGP-mediated efflux
Permeability essential; minimal
PGP-mediated efflux in cell lines
of interest
Chemically reactive groups None present unless a well
characterized and selective
mechanistic requirement
None present unless a well
characterized and selective
mechanistic requirement
None present unless a well
characterized and selective
mechanistic requirement
Molecular weight (Da) <500–550 <350–450 Likely to be <450
Lipophilicity (LogP) <5 <4 Likely to be <5
H-bond donors (O-H, N-H) = <5 <4–5 Likely to be <3
H-bond acceptors (N, O) = <10 <8–9 Likely to be <11
Rotatable bonds = <10 <8 Likely to be <10
Target potency (IC50 or Ki) 10
8–109 M 106–108 M 107–109 M
Ligand efficiency NA >0.3 kcal mol1 heavy atom1 NA
Target selectivity Well-defined selectivity;
polypharmacology acceptable
Well-defined selectivity; >10-fold
over related targets; minimal activity
on common off-targets, e.g., HERG
Well-defined selectivity; >10–100-
fold against closely related targets;
polypharmacology undesirable
Mechanism of action Activity in a relevant model
of the target disease
Well-defined quantitative
relationship between biochemical
and cellular effects consistent with
target-dependent action
Well-defined quantitative
relationship between biochemical
and cellular effects consistent with
target-dependent action
Pharmacokinetics Well-defined therapeutic window
and in vivo pharmacokinetics
Stable in microsomes; no CYP450
inhibition
Good pharmacokinetics not
essential for in vitro and cellular use,
but required for in vivo animal work
For references to specific suggested criteria see: A, Amidon et al., 1995; C, Cohen, 2009; Co, Collins and Workman, 2006; E, Edwards et al., 2009; F,
Frye, 2010; K, Kerns and Di, 2008; Ko, Kodadek, 2010; L1, Lipinski et al., 2001; L2, Lipinski, 2003; O, Oprea et al., 2007;W, van derWaterbeemd, 2002;
Wo, Wohnsland and Faller, 2001.
CaCo2: human epithelial colorectal adenocarcinoma cell line, CaCo-2: CYP450: cytochrome P450 enzymes, DMSO: dimethylsulfoxide, HERG: human
ether-a-go-go related gene product (Kv11.1 potassium ion channel), IC50: half maximal inhibitory concentration, Ki: inhibitor dissociation constant,
LogP: octanol-water partition coefficient, NA: not applicable, Pe: apparent permeability, PGP: p-glycoprotein.
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Perspectivewith regard to sensitivity to acid or base. Covalently reactive
functionality may be less problematic for chemical probes than
drugs (Kodadek, 2010), especially if linked to a specific target
mechanism, but caution is needed because nonspecific chemi-
cal reactivity may promote stress-related phenotypes in the
cell. Thus a lack of chemical functional groups and physico-
chemical properties known to elicit oxidative stress, redox
chemistry, membrane destabilization, or irreversible protein
binding is very desirable (Price et al., 2009).
Aqueous solubility and membrane permeability are of great
importance in providing usable chemical matter for cell-,
tissue-, or whole organism-based research, and assays for these
properties are now readily accessible (Kerns and Di, 2008).
For leads and drugs, adequate solubility and permeability are
required to achieve intestinal absorption and oral bioavailability
but they are also essential for probes of intracellular targets to
be useful in vitro. The achievement of pharmaceutical lead-like
pharmacokinetic properties may not be absolutely essential in
a chemical probe, but there are considerable advantages in
probes that can be progressed with confidence to an in vivo
whole animal setting. Similarly, the avoidance of adverse off-
target toxicological effects is important in a tool for use in animal
models; physicochemical properties as well as toxicophoreChemistry & Bigroups are important for this, with an increased likelihood of
toxic events being observed for less polar, more lipophilic
compounds across a broad range of chemical space (Hughes
et al., 2008). Thus the stringency of the fitness factors for
in vivo probes is higher than for biochemical or cellular probes.
The value of defining the physicochemical behavior of com-
pounds in drug discovery is well established. The widely used
Lipinski guidelines (known as the ‘‘rule of five’’) are aimed to
increase the likelihood that small molecules will have physico-
chemical properties compatible with the biological environment,
especially for oral bioavailability (Lipinski et al., 2001). On the
other hand, such probabilistic guidelines have many exceptions
and must be applied in context, and similar diligence should
be applied when assessing chemical probes according to phys-
icochemical parameters. Evidence-based guidelines for the
desirable properties of pharmaceutical lead-like molecules are
summarized in Table 1 and compared with those for typical
drug-like molecules (Collins and Workman, 2006) and those
emerging for chemical probes.
The discrimination between lead-like (or fragment-like) and
drug-like chemical space in terms of calculated molecular
properties (size, polarity, conformational rigidity, efficiency of
biological interaction) has been useful in drug discovery whereology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 565
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complexity as it is engineered to a clinical candidate. A satisfac-
tory probe may arise as a primary HTS hit and not require
addition of further functionality to enhance properties, although
iterative improvement to refine the probes is increasingly
expected (Edwards et al., 2009). Analyses of the footprint of
existing probes in chemical property space has shown inter-
esting concordance with that of high quality pharmaceutical
leads (Oprea et al., 2007; Lipinski et al., 2001) and there is recog-
nition that an iterative process of refinement of initial HTS hits is
required to generate high quality chemical probes—just as for
the progression of a pharmaceutical lead to a drug.
Although the experimental performance of a molecule is the
prime consideration, calculated property values may be useful
in guiding the design of new screening libraries for both pharma-
ceutical leads and chemical probes to increase the probability of
finding fit-for-purpose compounds. However, the necessarily
retrospective nature of such analyses biases the definition of
chemical space toward what is well known. Because chemical
probes are intended to be used at the leading edge of biological
research, it will be important to revise definitions of appropriate
chemical space to encompass as yet relatively unexplored
classes of target interactions, e.g., protein–protein interaction
inhibitors (Dobson, 2004; Sperandio et al., 2010).
Potency. The biological potency of a probe should be appro-
priate to the intended research. A useful consensus has emerged
in favor of <100 nM potency against the usually recombinant or
purified biochemical target and at least 1–10 mM potency in the
relevant cell-based system (Table 1) (Oprea et al., 2007; Frye,
2010; Edwards et al., 2009). A concentration-dependent effect
of the probe on the target gives confidence in a targeted mech-
anism (Frye, 2010), and this may be supplemented by the avail-
ability of close analogs of the probe with varying degrees of
activity. If a probe is to be useful for in vivo experiments in whole
animals then the relationship of the potency to the in vivo phar-
macokinetic properties should be evaluated to provide confi-
dence that sufficient levels of the compound will be achieved
in the target tissues. The availability of a suitable pharmacody-
namic biomarker that shows engagement of the chemical probe
with the target in cells and also in vivo in animal models is very
valuable in this context (Workman, 2003).
Selectivity. The selectivity of probes is very important because
they are intended as highly specific pharmacological modulators
(Cohen, 2009; Frye 2010). It could be advisable to reconsider the
selectivity profile of existing probes each time they are used in
new biological settings where distinct confounding factors may
be present (see more on context below).
The typical selectivity criteria for refined chemical probes
(>10–100-fold over related targets; Table 1) may be more strin-
gent than those for pharmaceutical leads because no further
engineering of the former molecules is envisaged, and thera-
peutic polypharmacology is more likely to be acceptable (and
sometimes may even be essential, as in multi-targeted protein
kinase inhibitors) in a drug (Kodadek, 2010).
Large scale in vitro selectivity profiling is often recommended,
particularly for kinase inhibitors (where several tens or hundreds
of kinasesmay be tested) but also for modulators of other protein
superfamilies (Fabian et al., 2005). We suggest that selectivity
testing against at least 50 carefully chosen kinases is appropriate566 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigfor assessing kinase inhibitor probes. Although this profiling can
yield valuable information, it is important not to generate a false
sense of security. For example, biochemical kinase inhibition
profiles require interpretation to predict the likely cellular conse-
quences (Smyth and Collins, 2009) and inhibitors may interact
with other target families that may not be looked at (Bantscheff
et al., 2007). Nevertheless, at some point on their journey chem-
ical tool compounds ideally need to be well characterized
in terms of broad ligand pharmacology, including effects on
G protein coupled receptors, nuclear receptors, ion channels,
kinases, phosphatases, proteases, and ubiquitin ligases (Entzer-
oth et al., 2000). Such broad profiling can rule out promiscuous
pharmacology or activity on particular anti-targets.
The cost of selectivity screening in focused or broader phar-
macology panels may be restrictive, particularly for academic
groups and small companies. Useful pharmacological data
on approved drugs can often be found in the disclosures
that accompany regulatory approval (www.accessdata.fda.
gov/scripts/cder/drugsatfda/index.cfm). Nonbiased global gene
expression profiling can provide a valuable means of assessing
on- and off-target effects in cells, with connectivity maps linking
the profiles to targets (Clarke et al., 2001; Lamb et al., 2006;
http://www.broadinstitute.org/genome_bio/connectivitymap.
html).
Selectivity screening can be supplemented by using control
compounds in biological experiments, especially inactive or
weakly active analogs from the same chemical scaffold, some-
times conveniently referred to as a chemotype, together with
active analogs of a different chemotype. Examining concentra-
tion-dependency and structure-activity relationships (SAR) from
these analogs compensates for the deficiencies of any one
compound and thus triangulates the target-dependent pheno-
type, especially when the SAR for molecular biomarker changes
that are associated with target modulation also correlate with
cellular outcome (Cohen, 2009; Frye, 2010; Kodadek, 2010).
This can be seen as an application of the ‘‘pharmacological audit
trail’’—used tobuildconfidenceduringdrugdevelopment—at the
biochemical and cellular level (Workman, 2003; Yap et al., 2010).
These days, chemical probes frequently arise from large scale
library screening that will often produce clusters of chemically
related compounds of varying activity, so access to suitable
analogs is not necessarily restrictive for academic groups
(Inglese et al., 2007). Interrogating the burgeoning databases
that annotate chemical structure with biological information will
also inform on potential selectivity issues (Tolliday et al., 2006;
Huryn and Cosford, 2007; Petri Seiler et al., 2008; Keiser et al.,
2009; http://www.ebi.ac.uk/chembl). It will be important to apply
the fitness factors under discussion here in evaluating historical
data retrieved by such chemoinformatics methods, and to
assess the reliability of the associations uncovered depending
on the suitability and application of the probes concerned.
Context. Biological context is everything when discussing
chemical tools. In stressing this, we emphasize that the appropri-
ateness of a probe’s use cannot necessarily be extrapolated
from one biological system to another. The intended use will
govern the suitability of a probe as well as the compound’s
intrinsic properties (Table 1). What is desirable is a suite of chem-
ical probes and techniques, appropriate to the target and scien-
tific question under investigation, i.e., fit-for-purpose, that allowshts reserved
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Perspectivea consensus to be built about the role of a given target in a partic-
ular mechanism from multiple approaches. Thus complimentary
genetic methods, such as specific RNAi or mechanism-based
mutants of the target protein are recommended to reinforce
the data from chemical probes while remaining aware of the
differences between the techniques (Weiss et al., 2007; Cohen,
2009; Frye 2010).
An example of the dependence on context in oncology is the
assessment of the activity of targeted probes or drugs in large
panels of cancer cell lines with defined mutational, gene expres-
sion and other molecular characteristics (see http://www.
sanger.ac.uk/genetics/CGP/cosmic/ for information on cancer
genemutations). Markedly differential effects on cell proliferation
or apoptosis are seen depending on a given compound’s selec-
tivity profile combined with the cell’s genetic/molecular profile
(Sharma et al., 2010). Indeed, there is considerable power in
interrogating many different cell types with a range of well-
validated probes. The chemical probes are used to help under-
stand the biology of the cell lines and the effects in the cell
lines help to credential the probes (http://www.sanger.ac.uk/
genetics/CGP/Translation).
That repetition of biological profiling in multiple relevant bio-
logical systems and in different laboratories is a key part of
chemical probe validation is to be emphasized. An important
fitness factor for context is to consider the question: is this the
best probe to use for this purpose? There may be several probes
available targeted to a particular pathway or molecular target,
and the properties of certain compoundsmay be better matched
to some biological systems than others and more capable of
yielding a robust test of the biological hypothesis under investi-
gation. For example, minimizing the risk of inhibition of particular
confounding anti-targets in the biological system by avoiding
a chemotype with those activities.
In addition to the uses of biomarkers described earlier, consid-
erable value can be added to the probing of probes by using
biochemical andmolecular biomarkers to characterize the target
cells of interest and then to evaluate the effects of the probes for
on-target and off-target pathways in those cells (e.g., Banerji
et al., 2005; Guillard et al., 2009; Raynaud et al., 2009).
Biomarkers provide an important step in the pharmacological
audit trail referred to earlier, helping to establish that the chosen
chemical probe is fit for purpose in a specific context. Ideally,
quantitative biomarker methods should be used so that the
degree of target modulation can be determined and results inter-
preted accordingly. The interpretation of the effects of a probe
on a cellular phenotype (e.g., proliferation, apoptosis, differenti-
ation, migration, or other specific functions) is much more
powerful if validated biomarkers are used to demonstrate that
the probe is actually modulating the intended target and cognate
biochemical pathway (e.g., Solit et al., 2006). In addition, of
course, the probe compounds can be used to validate the
proposed biomarkers.
Probe Availability, Transparency of Reporting,
and Funding
The origin, identity, and properties of a compound proposed as
a chemical probe should be disclosed fully, and it should be
available in appropriate amounts for follow-up studies. The
different availabilities of chemical probes may in practice be
the dominant factors in determining which compound is used,Chemistry & Biand availability is therefore an important fitness factor. Wide-
spread availability of a probe and its associated data throughout
the global scientific community is highly desirable. Provided
that structures and synthetic methods are fully disclosed in
scientific publications and patents, it should generally be pos-
sible to make the required compound, or have it made. There
is an increasing tendency for probe compounds and drugs to
be sold by commercial suppliers. Commercial supply can reduce
the otherwise onerous demands on academic labs and com-
panies to provide compounds from finite resources. Some
pharmaceutical companies have taken the initiative of making
probes available via commercial vendors (e.g., http://investor.
sigmaaldrich.com/releasedetail.cfm?releaseid=451709). There
may, however, be a need for new thinking to further improve
the availability of probes throughout the research community,
taking into account legal considerations around research use
and supply of proprietary compounds. Obtaining larger quanti-
ties for animal studies can be especially challenging.
For a given target, we strongly recommend the use of probes
from more than one chemical scaffold and also inclusion of
negative control analogs. Despite their importance, companion
inactive or other analogs are rarely available commercially. In
the light of the selectivity fitness factors discussed above it could
be desirable to consider chemical probes as reagent sets con-
sisting of a pair of active and inactive compounds from the same
chemotype, ideally together with an active compound from
another chemical scaffold, in the same way that gene silencing
studies using small interfering RNA reagents is typically con-
ducted with multiple effective RNA oligomers together with
appropriate negative control sequences.
Several previous publications rightly stress the need for trans-
parency in reporting all relevant data on proposed new probes
as well as the desirability of unrestricted or ‘‘open access’’ avail-
ability (Oprea et al., 2007; Edwards et al., 2009; Cohen, 2009;
Anonymous, 2010). Transparency on reporting findings is impor-
tant so that data from all probes, whether the compound is freely
available or proprietary, can be assessed with confidence and
equal rigor.
What about funding for all this probing of probes? Very
detailed profiling is expensive and the scale is increasing.
Much of this work will be carried out using conventional support
in academia and industry. Making probes widely available
will mean that the international scientific community can put
them through an enormous range of biological assays, thus
building up a profile of information in an open access fashion
that is similar to other fields such as software development
and genome sequencing. Maintaining quality and having data-
bases and tools to access this information is increasingly
important (e.g., http://pubchem.ncbi.nlm.nih.gov/; www.ebi.ac.
uk/chembl/).
Special initiatives are also appropriate. The NIH MLI is one
approach funded publically that seeks to build on success with
large scale genome sequencing projects (Austin, 2003; Oprea
et al., 2009). Oprea et al. (2009) discuss United States funding
mechanisms that might be used to support probing the probes.
Public–private partnerships have been initiated as a new funding
model with the aim of developing open access chemical probes
against pioneer targets such as chromatin modifying enzymes
(Edwards et al., 2009).ology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 567
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Figure 2. Fitness Factor Liabilities for
Selected Early Chemical Probe Inhibitors of
Protein Kinases, the PI3K Family of Lipid
Kinases and the HSP90 Molecular
Chaperone
Important fitness factors that have been improved
significantly in subsequent chemical probes and
clinical agents acting on these targets have been
flagged. The symbols refer to the fitness factors
listed in Figure 1, and the evolution of the probes
to remove the liabilities shown is discussed in
detail in the respective sections of the text.
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PerspectiveEvolving Probes: One Size Does Not Fit All
We emphasize that the fitness factors in Figure 1 and the
threshold values in Table 1 represent guidelines rather than
proscriptive rules. Particularly when a molecular target or
biological area is new, useful information can still be gained
with a chemical probe that is not yet ideal (see examples later),
and indeed may have obvious limitations with respect to
fitness factors. Emerging probes will be road-tested by the bio-
logical community. They will embark on an evolutionary journey,
struggling with other probes for survival. Unfit ones will be dis-
carded whereas fit-for-purpose tools will be taken up and used.
Improved probes will then emerge into the light and the chem-
ical tools will evolve alongside the biological understanding.
It is clearly important thatwhennewprobes doemerge theyare
compared with the current best in class and that the added value
is clear (Oprea et al., 2009). Asmentioned, poor chemical probes
can mislead biologists. But we also believe that excessive
prescription will run counter to innovation. Potentially important
probes in a new biological area must not be damned too quickly
because theyhavea few roughedges.On theother hand, consid-
ering the fitness factors can help decide when a probe is fit-for-
purpose, should encourage good practice and should avoid
the worst examples that continue to contaminate the literature.
Examples of the sort of experience that has been gained with
probing probes and evolving tools will be found in the oncology
case histories discussed in the following sections. As an illustra-
tion, Figure 2 shows the limitations in fitness factors for selected
early chemical probe inhibitors of the three classes of important
targets that will be considered in detail, namely protein kinases,
the PI3K family of lipid kinases, and the HSP90 molecular chap-
erone. In each case, the early probes were flawed but neverthe-
less proved useful, and the fitness factor profile was enhanced
considerably during subsequent probe evolution, such that the
liabilities were effectively removed.
Chemical Probes for Protein Kinase Inhibition
The close links between chemical biology and drug discovery
are amply illustrated by the coevolution of protein kinase inhibitor568 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reservedtool compounds and pharmaceutical
leads. Selectivity has been a key fitness
factor consideration in protein kinase
research, as will be highlighted.
Using and Improving Staurosporine
The natural product staurosporine (Tam-
aoki et al., 1986) (for the chemical struc-
ture of this and other selected proteinkinase inhibitors, see Figure 3) has been a widely used probe
of signal transduction biology in cells but has significant liabilities
in its fitness factors (Figure 2). The compound and its analogs are
now seen as unacceptably promiscuous (Bain et al., 2007; Frye,
2010). Very high binding to human plasma proteins was seen in
clinical trials of the staurosporine analog UCN-01 (Fuse et al.,
2005). Hypotheses based on the activities of the indolocarba-
zoles have nevertheless been productively investigated, and
over time compounds with better utility have been developed
(Nakano and Omura, 2009). The distinctive effect of the com-
pounds on tumor cell cycle progression and apoptosis was orig-
inally interpreted as inhibition of protein kinase C (PKC), but it
became apparent that a much wider range of protein kinases,
or nonkinase targets, were inhibited (Akinaga et al., 2000;
Prudhomme, 2003).
Substantial medicinal chemistry efforts were made to tease
apart the activities of the indolocarbazole early leads (Roffey
et al., 2009). For example, the bisindolylmaleimide ruboxistaurin
(LY333351) was generated with somewhat improved selectivity
for PKC (Jirousek et al., 1996; Bain et al., 2007). More recently,
sotrastaurin (AEB071) has been reported as a potent and highly
selective inhibitor of PKC isoforms (Wagner et al., 2009), as illus-
trated in the kinome profiles in Figure 4. Interestingly, the anilino-
pyrimidine scaffold that led ultimately to the BCL-ABL inhibitor
imatinib, the first approved kinase-targeting anticancer drug,
was discovered initially in a project to find new PKC inhibitors
(Capdeville et al., 2002). It is also important to note that for struc-
tural biology studies involving wide comparisons across the
kinase superfamily, the promiscuity of staurosporine has actually
been exploited as a useful property (Tanramluk et al., 2009).
In addition, probably because of its promiscuous effects, staur-
osporine is frequently used as a control compound in studies of
apoptosis.
Elucidation of the multifactorial effects of the staurosporine
analog UCN-01 on tumor cells led to an understanding of the
role of the cell cycle regulator CHK1 (Senderowicz, 2000).
UCN-01 and more selective inhibitors of checkpoint kinases,
such as isogranulatimide (Jiang et al., 2004), abrogate the S
Figure 3. Structures of Selected Protein Kinase
Chemical Probes Discussed in Detail in the Text
with Their Main Proposed Targets Indicated
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PerspectiveandG2 checkpoints induced by DNA-damaging agents and thus
potentiate their cytotoxicity. This exemplifies the use of multiple
compounds to build confidence in the association of an effect
to a particular target even where specificities are not high
(Collins and Garrett, 2005). Selective inhibitors of CHK1, or
dual inhibitors of CHK1 and CHK2, have now been developed
and clinical trials are ongoing with agents including AZD7762,
PFZ00477736, and SCH900776 (Bucher and Britten, 2008; Dai
and Grant, 2010), whereas highly selective inhibitors of CHK1
have been identified as chemical probes with good performance
across the fitness factors, e.g., SAR-020106 (Walton et al.,
2010).
Thus it is clear that with all the limitations of staurosporine, it
has provided the inspiration for a new generation of robustly
fit-for-purpose probes with excellent fitness factor profiles for
in vitro and in vivo use, as well as drugs in the clinic.Chemistry & Biology 17, June 25From Tyrphostins and Purines to Clinical
Candidates
An early breakthrough in the development of
chemical probes for kinases came with the
rational design of the tyrphostin inhibitors of
receptor tyrosine kinases (RTK) (Gazit et al.,
1989). These compounds have poor chemistry
fitness factors due to the presence of functional
groups widely considered as undesirable, in
particular polyphenolic residues associated
with nonspecific protein binding and redox
metabolism, as well as chemically reactive ben-
zylidenemalononitriles. Some tyrphostins were
later shown to uncouple the mitochondrial
electron transport chain leading to ATP deple-
tion and generalized inhibition of intracellular
kinase signaling (Soltoff, 2004). Nevertheless,
the tyrphostins were important pathfinder com-
pounds that provided impetus for research
into kinase inhibition, showing the ability to
achieve selectivity at the ATP site, and leading
to more refined chemical probes, as in the
pioneering example of the epidermal growth
factor (EGFR) RTK enzyme (Yaish et al., 1988;
Levitski and Gazit, 1995). Following on, the ani-
linoquinazolines were an early, more drug-like
scaffold providing stable and selective RTK
inhibitors with much improved fitness factor
profiles (Fry et al., 1994). This chemical class
has since provided a plethora of excellent
in vitro and in vivo probes and clinical candi-
dates, including the approved drugs gefitinib,
erlotinib, and lapatinib that show cellular and
clinical activity in the context of genetic muta-
tion or amplification of the EGFR and ERBB2
RTKs (Barker et al., 2001; Pollack et al., 1999;
Xia et al., 2002).A number of chemical probes for protein kinases evolved from
structures inspired by the purine cofactor ATP (Vesely et al.,
1994). The development of purine-derived inhibitors is an early
example of the successful generation of novel probes through
the application of combinatorial library synthesis combined with
structural biology (Gray et al., 1998). Several purines, including
seliciclib (R-roscovitine; Meijer et al., 1997) that is now in clinical
trial for cancer (Whittaker et al., 2004; Benson et al., 2007), are
appropriate probes for pan-cyclin dependent kinase (CDK)
inhibition (Bain et al., 2007). The identification and refinement of
other CDK inhibitor chemotypes has provided isoform-selective
compounds, such as the pyridopyrimidinone CDK4/6-selective
inhibitor PD 0332991 or the aminothiazole CDK2/7/9 inhibitor
SNS-032 (Toogood et al., 2005; Misra et al., 2004). Importantly,
the molecularly targeted drug discovery efforts again progress
hand-in-hand with the evolution of better chemical probes., 2010 ª2010 Elsevier Ltd All rights reserved 569
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Figure 4. Evolution of Increasingly Selective PKC Inhibitors Based on Staurosporine
Percentage inhibitions for UCN-01 and ruboxistaurin were measured at 0.01 mM and 0.1 mM concentrations, respectively, for the same panel of 69 kinases
(Bain et al., 2007). IC50 values were determined for sotrastaurin in a panel of 32 kinases (Wagner et al., 2009). The cluster of potent activities for sotrastaurin repre-
sents PKC isoform inhibition. All three compounds inhibit several PKC isoforms with IC50 0.001–0.01 mM. Kinase dendrogram (Manning et al., 2002) reproduced
courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com).
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To find highly selective chemical probes for kinases, there may
be advantages in specifically targeting distinct inactive confor-
mations of the ATP-binding site (Liu and Gray, 2006) or true allo-
steric modulatory sites, as demonstrated with selective AKT
inhibitors (Cherrin et al., 2010).
The ATP noncompetitive inhibitor of MEK1/2 (MKK1/2),
U0126, was identified from a cell-based screen for inhibitors
of AP-1 mediated transcription (Duncia et al., 1998; Favata
et al., 1998). The compound prevents activation of MEK1/2,
leading to high potency in cells for inhibition of the RAF-
MEK-ERK cascade. The 1,4-diamino-2,3-dicyanobutadiene
moiety is an interconvertible mixture of steroisomers in solu-
tion, where activity resides uniquely in one isomer. Although
unstable structures may be generally undesirable in chemical
probes, the chemical behavior was reported and understood
at an early stage, and U0126 has proved a useful chemical
tool (Davies et al., 2000; Bain et al., 2007). HTS for other che-
motypes of MEK ligand identified the chromenone PD 098059
as an alternative noncompetitive inhibitor with improved chem-
ical fitness factors (Dudley et al., 1995), and MEK inhibitor
development has led to enhanced, highly selective chemical
probes and clinical candidates, including PD 184352, PD
0325901, and AZD6244 (ARRY142886) (Bain et al., 2007; Hali-
lovic and Solit, 2008).
Structural biology studies with an analog of PD 184352 (PD
318088) showed the inhibitors to bind in an allosteric pocket
adjacent to the ATP-binding site ofMEK1/2, locking the enzymes
in the unphosphorylated, inactive form (Ohren et al., 2004).570 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigThe inhibitor PD 0325901 has been used as a cellular mecha-
nistic probe to reveal biology context-dependent, selective ther-
apeutic effects in that tumor cells driven by mutant BRAF have
a unique vulnerability to MEK inhibition (Solit et al., 2006)—an
effect also recapitulated recently both in cells and in the
clinic with selective ATP-competitive BRAF inhibitors, whereas
enhanced tumor progression is seen in cancers with NRAS
mutations (Heidorn et al., 2010). Bain et al. (2007) recommend
the use of PD 184352 or PD 0325901, with confirmation by the
structurally unrelated U0126, as probes to inhibit MEK in cells.
Chemical Genetics and Kinase Inhibitors
An example of the development of protein kinase inhibitor chem-
ical probes highlights the complementarity between chemical
and genetic approaches. The pyrazolopyrimidines PP1 and PP2
were identified as inhibitors of SRC family kinases (Hanke et al.,
1996). Structural studies showed the importance of a small
gatekeeper residue and accessibility of the interior hydrophobic
pocket of the kinase in determining the selectivity of the pyrazo-
lopyrimidines (Liu et al., 1999). Exploiting this paradigm, mutant
protein kinases where a large gatekeeper residue is replaced by
alanine can be rendered sensitive to the pyrazolopyrimidines
NM-PP1 and NA-PP1 that bear large substituents not generally
tolerated bywild-type kinases (Bishop and Shokat, 1999). Trans-
fection of cells with the drug-sensitized mutants thus allows
highly selective, rapid, and reversible pharmacological inhibition
of the target enzyme to be probed. However, NM-PP1 and
NA-PP1 do inhibit some wild-type kinases and this should be
taken into account in interpreting results from gatekeepermutant
proteins (Bain et al., 2007).hts reserved
Figure 5. Structures of Selected PI3 Kinase and HSP90 Chemical Probes Discussed in Detail in the Text with Their Main Proposed Targets
Indicated
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mutant kinase alleles have also proved to be very useful (Brown
et al., 1995; Eyers et al., 1999; Cohen, 2009) and are recommen-
ded for additional security as regards selectivity, alongside the
use of two distinct chemotypes and inactive controls when
interrogating kinase probe selectivity in cells (Cohen, 2009).
For example, the cellular expression of BRAF alleles with mutant
gatekeeper residues rendering them resistant to inhibition by
small molecules has clearly shown that the multi-RTK inhibitor
sorafenib does not exert its cellular antiproliferative effects
through inhibition of BRAF, in contrast to the more recently
developed inhibitor PLX4720 (Whittaker et al., 2010).
Protein kinase inhibitors provide arguably the best examples of
context-dependent effects, with agents (such as imatinib in BCR-
ABL positive or KIT mutant cancer cells, or the EGFR and ERBB2
inhibitors in cells with mutated and amplified targets) exhibiting
selective antiproliferative and apoptotic outcomes in cells that have
become ‘‘addicted’’ through, for example kinase mutation, amplifi-
cation or translocation (Weinstein, 2002; Collins and Workman,
2006). Importantly, the same effects are also seen in the clinic.
Chemical Probes for PI3 Kinases
Phosphatidylinositide 3-kinases (PI3Ks) are key components of
signal transduction pathways controlling a wide range of biolog-Chemistry & Biical phenotypes and are deregulated in several diseases
including immune inflammation and cancer. These lipid kinases
phosphorylate the 30-hydroxy position of the inositol ring of
phosphoinositides (PI) generating PI second messengers down-
stream of RTKs and G protein coupled receptors. In parallel with
biochemical and genetic studies (Cantley, 2002), our current
understanding of the biological roles of PI3Ks has benefited
enormously from the use of chemical probes over the last 20
years (Workman et al., 2010).
Flawed but Valuable Early PI3K Probes
Starting from probes that are now known to have significant limi-
tations but which have proved useful in thousands of studies,
these have evolved into more sophisticated chemical tools
with much more attractive fitness factor profiles and also into
the first PI3K drugs entering the clinic for cancer treatment
(Workman et al., 2010).
The fungal furanosteroid metabolite wortmannin (see Figure 5
for the chemical structure of this and other selected PI3K inhib-
itors) was identified in 1987 as a potent inhibitor of the respiratory
burst in neutrophils and monocytes (Baggiolini et al., 1987) and
subsequently found to inhibit PI3K by covalent binding to
a specific ATP site lysine (Wymann et al., 1996). LY294002,
a synthetic chromone related to the bioflavonoid and broad
spectrum protein kinase inhibitor quercetin, was discovered inology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 571
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assay and was found to inhibit PI3K competitively at the ATP
site (Vlahos et al., 1994). Wortmannin is potent but unstable
and was shown by profiling to inhibit smMLCK, PLK1, PI4K,
and mTOR (Bain et al., 2007). Like wortmannin, LY294002 also
has major defects in its fitness factors (Figure 2). It is only
a weak PI3K inhibitor with a Ki of 1.6 mM, and activity in cells at
10–50 mM, and is also active against TORC1, CK2, PLK1,
PIM1, PIM3, HIPK2, and GSK3, as well nonkinase off-targets,
at concentrations similar to those that inhibit PI3K (Davies
et al., 2000; Bain et al., 2007; Gharbi et al., 2007). Despite these
limitations, wortmannin and LY294002 were used to generate
invaluable understanding of physiological and pathological
processes and to validate PI3K as a druggable target.
Evolving to Enhanced PI3K Probes and Drugs
in the Clinic
Over the last few years, combinations of screening, medicinal
chemistry, and structure-based design approaches have gener-
ated an exciting series of enhanced probes and drug candidates
with markedly improved properties in respect of all of the fitness
factors (Shuttleworth et al., 2009). A compound that is now rec-
ommended (Bain et al., 2007) as a chemical tool for class I PI3K/
mTOR is the pyridofuropyrimidine PI-103 that has single digit
nanomolar target potency, shows a high degree of selectivity
against at least 70 kinases, and exhibits activity against animal
models of cancer (Hayakawa et al., 2007; Raynaud et al., 2007).
Optimization of PI-103 to reduce metabolic clearance and
improve its pharmacokinetic properties resulted in the thienopyr-
imidine GDC-0941 that is now in Phase I clinical trials for cancer
(Folkes et al., 2008; Raynaud et al., 2009). As with PI-103,
detailed and quantitative molecular biomarker studies confirmed
inhibition of the PI3K pathway in cells. GDC-0941 has the overall
profile of a potent Class I PI3K inhibitor (acting at low nanomolar
concentrations on all the class 1A isoforms p110a, p110b, and
p110d and the single class 1B isoform p110g) with very high
selectivity versus class II and III PI3K superfamily members.
In contrast to PI-103, GDC-0941 also has low activity on the
class IV PI3K superfamily protein kinases, including mTOR.
Broader profiling showed that GDC-0941 is highly selective for
PI3K with respect to a panel of 228 protein kinases. As would
be required of a clinical candidate, GDC-0941 has negligible
effects on CYP1A and CYP3A4 with no significant blockade of
the HERG channel by patch clamp assay. A number of PI3K
inhibitors are now in the clinic (Yap et al., 2008; Shuttleworth
et al., 2009), including the imidazoquinoline NVP-BEZ235 that
evolved by target hopping from a PDK1 inhibitor lead (Liu
et al., 2009).
Understanding Selective PI3K Inhibition through Probes
and Protein Structure
Obtaining selectivity among the Class I lipid kinases in the PI3K
superfamily has been an important goal for probes and drugs.
In a landmark chemical biology study, large numbers of PI3K
inhibitors from journal articles and patents were synthesized
and profiled against multiple enzymes (Knight et al., 2006),
revealing intriguing cryptic homologies across PI3K targets
and chemotypes. Clear selectivity trends were uncovered
that were not predicted from the amino acid sequences. In terms
of the use of these agents as chemical probes, the matrix of
PI3K inhibitors was used to confirm the key role of p110a in572 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All riginsulin signaling, consistent with the mutant p110a mouse
knock-in studies published around the same time (Foukas
et al., 2006)—an example of chemical probe and genetic studies
validating contemporaneously the same cutting edge biological
result.
Of note, structural biology and modeling approaches have
played a leading role in the design of PI3K inhibitors and in the
interpretation of their potency and selectivity fitness factor prop-
erties (Workman et al., 2010). Pioneering X-ray crystal structures
were obtained byWalker et al. (1999) for the apo and ATP-bound
forms of p110g and for early probes like wortmannin and
LY294002 bound to this isoform (Walker et al., 2000). The X-ray
structure of GDC-0941 explained its improved potency (Folkes
et al., 2008). Very recently, structures of inhibitors complexed
with the p110d subunit have been determined, e.g., the quinazo-
line IC87114, which facilitated the design of new propeller-
shaped compounds selective for the more conformationally
flexible ATPsite of this isoform (Berndt et al., 2010). Agents selec-
tive for p110d and p110g have potential in diseases such as
immune inflammation and cancer, as well as being powerful
chemical probes, including the p110d clinical drug CAL-101
derived from IC87114 (Shuttleworth et al., 2009).
The very recently solved crystal structure of the class III PI3K
Vps34, which is involved in autophagy, membrane trafficking
and cell signaling, shows why it is so difficult to inhibit (Miller
et al., 2010). A very weak Vps34 inhibitor, 3-methyladenine,
has been used at 10 mM as a ‘‘specific’’ inhibitor of autophagy.
New cocrystal structures of Vps34 with inhibitors have pointed
theway to novel compoundswith greater potency and selectivity
over class I PI3Ks, highlighting the potential for probes with
much better fitness factors for blocking Vps34 and autophagy
in cells.
Using PI3K Probes
The testing in parallel of more than one probe chemotype, e.g.,
wortmannin plus LY294002 or PI-103 for class I lipid kinases,
has been quite common in PI3K research. The application of
companion inactive derivatives has been much less common,
although early cellular work with LY294002 used analogs that
were substituted in the essential morpholine ring to reduce
hinge-binding (Vlahos et al., 1994). In terms of cellular context,
cancer cells with mutations in the PIK3CA gene encoding
p110a, or loss of the counteracting phosphatase PTEN,
may be more sensitive to pan-class I selective PI3K inhibitors,
whereas mutations in KRAS seem to confer resistance
(Workman et al., 2010). As with protein kinases, the PI3K family
is another excellent example of a target group for which the
fitness factors of the probe compounds were initially less than
we would now desire, but which were nevertheless sufficient to
move the field forward markedly, leading through iterative
improvements to the highly potent and selective probes
that are available commercially and drugs that are now in the
clinic.
Chemical Tools for the HSP90 Molecular Chaperone
HSP90 is a molecular chaperone that helps to control the stabi-
lization and degradation of its ‘‘client’’ proteins, aswell regulating
their activated states (Workman et al., 2007). It has emerged as
an exciting oncology target because inhibiting HSP90 causes
depletion of multiple oncogenic clients, e.g., mutant kinases,hts reserved
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the antagonism of the hallmark pathological traits of malignancy.
Cancer selectivity is achieved by exploiting oncogene addiction
as well as the stressed state of tumor cells (Workman et al.,
2007).
Natural Product Origins of HSP90 Probes
HSP90 is an outstanding example of a contemporary pioneer
drug target for which chemical probes played a leading role in
the elucidation of the physiological and pathological functions
of the protein, aswell in establishing its druggability and reducing
biological risk as perceived by industry. In particular the natural
products geldanamycin and radicicol (Figure 5) were found in
landmark studies in the 1990s to bind HSP90, specifically at its
unusually shaped GHKL class of ATP-binding site, and thereby
to inhibit the essential ATPase-driven chaperone cycle, resulting
in client protein degradation (Whitesell et al., 1994; Roe et al.,
1999). These valuable early natural product HSP90 probes
turned out to be quite potent and selective for HSP90 with
respect to the isolated biochemical target and also in cells.
However, they nevertheless have other significant fitness factor
limitations, particularly the metabolically labile quinone in gela-
danamycin (Figure 2) and the reactive epoxide group in radicicol,
as well as other metabolism/stability issues, efflux pump and
cytochrome P450 liabilities, and general toxicity problems.
Structure-Based Design of HSP90 Probes and Drugs
In parallel with the 17-allylamino analog of geldanamycin (17-
AAG, tanespimicin) being developed for clinical evaluation,
efforts were initiated to identify synthetic small molecule inhibi-
tors that lacked the obvious undesirable features of the path-
finder natural products (see Figure 5 for the chemical structures
of HSP90 inhibitors discussed in text). The purine PU3, designed
by structure-based modeling, led the way; although showing
only 15–20 mM potency on HSP90, it depleted specific chap-
erone clients in cancer cells, confirming an on-target mecha-
nism (Chiosis et al., 2001). Optimization produced more
potent purines, such as the in vivo active PU24FCl (Vilenchik
et al., 2004) and the nanomolar potent, orally active clinical
candidate BIIB021/CNF-2024 (Kasibhatla et al., 2007; Zhang
et al., 2010).
The pyrazole/isoxazole resorcinol class of synthetic small
molecule inhibitors was identified by biochemical screening.
The original HTS hit CCT018159 was ATP-competitive with a
Kd of 0.5 mM and, like PU3, caused client depletion in cancer
cells; an indication of selectivity was shown by the relative lack
of activity on the related GHKL class protein topoisomerase II
and 20 protein kinases (Cheung et al., 2005; Sharp et al.,
2007). X-ray crystallography confirmed a resorcinol-anchored
binding mode identical to the natural product radicicol. Struc-
ture-based multiparameter optimization yielded the clinical
candidate NVP-AUY922, now in Phase II trials (Brough et al.,
2008; Eccles et al., 2008). This had a Kd of 2 nM, showed mech-
anism-based inhibition of cancer cell proliferation at 9 nM and
exhibited potent antitumor activity in animal models. A high level
of selectivity for NVP-AUY922 was shown for the HSP90 a and
b isoforms, as compared to the closely related HSP90 family
chaperones GRP94 and TRAP-1, the GHKL superfamily member
topoisomerase II and the structurally distinct molecular chap-
erone HSP72, as well as 13 representative kinases, 14 additional
enzymes, and 67 receptors (Eccles et al., 2008).Chemistry & BiA range of additional HSP90 inhibitory chemotypes have
emerged recently (Biamonte et al., 2010), including clinical
candidates like the pyrazolobenzamide SNX-5422 (Huang
et al., 2009a) and the imidazopyridine CUDC-305/Debio 0932
(Bao et al., 2009).
Value of HSP90 Biomarkers Alongside Probes
The mutually enabling advances in basic, translational and
drug discovery research on HSP90 have been facilitated espe-
cially by the combined use of chemical probes and mecha-
nism-based molecular biomarkers. Early work identified the
depletion of clients and activation of heat shock proteins as
a direct result of HSP90 inhibition and these were also used to
show target modulation by 17-AAG in cancer patients (Banerji
et al., 2005). Further on-target versus off-target effects were
revealed by comparing the unbiased global expression profiles
for tumor cells treated with 17-AAG, an inactive analog and rad-
icicol as an alternative active chemotype (Maloney et al., 2007).
Interestingly, the upregulated gene products observed in that
profiling study included members of the HSP70 family, HSP72
and HSC70, which have chaperone and antiapoptotic proper-
ties. This has led to these proteins being validated recently as
cancer targets using RNAi together with several chemical probes
of varying quality that collectively give some reassurance of
potential druggability (Powers et al., 2008; Powers et al., 2010).
Chemical Tools for Other Oncology
Targets–Supplemental Information
In the Supplemental Information available online, we highlight
briefly a number of chemical probes (see Figure S1) for a range
of additional oncology targets of different structural and func-
tional types. These are selected as being of current interest to
both basic and drug discovery research. They include p53 and
BCL2 as good examples of important protein–protein interac-
tion targets; chromatin-modifying enzymes, particularly histone
deacetylases (see Figure S2), phosphatases; poly(ADP)ribose
polymerase (PARP); and tankyrase. Some of themprovide excel-
lent additional examples of context-dependent biological effects
of chemical probes and drugs, exploiting oncogene addiction
and synthetic lethality in certain cancer cells in the context of
particular mutation profiles.
Conclusions and Outlook
The field of chemical biology has matured in approach but is still
growing fast in scale – and in a way that makes the emergence of
guidelines for chemical probes almost inevitable. Given that
analogous guidelines have been useful with fragments, leads
and drugs in pharmaceutical discovery research, it seems likely
that comparable guidance for probes will also be very valuable.
Yet there are dangers. Taking deliberately extreme positions on
this, the upside is that the following of sensible guidelines will
result in probes that do what it says they should do on the tin
and hence will prove to be useful research reagents; whereas
the downside is that slavish adherence to a rule book could stifle
innovation, particularly in the early stages of work on a new target
or pathway for which probes are lacking.
We argue here that the correct strategy is somewhere in
the middle. We recommend a common sense, fit-for-purpose
approach and provide easy to use guidance on fitness factors
for small molecule probes (Figure 1). These fitness factorsology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 573
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Perspectiveencompass four important areas—chemical properties, biolog-
ical potency, biological selectivity, and context of use—that
between themdefine the appropriateness of using a given chem-
ical probe for exploratory biology. It is clearly not absolutely
essential for all the requirements to be met at the level proposed
by us and others. The case histories described here show that
valuable progress can be made with initial probes that may
well be suboptimal. At the same time, striving toward highly
potent and selective cell permeable probes that are free of
unnecessary chemical or biological baggage is highly desirable.
Proponents of new probes and those who use them should be
aware that suboptimal probes carry with them significant risk
of off-target biological effects that may be general or context-
dependent. The field should support transparency and avail-
ability of chemical probes so that the profiling and evidence-
based refinement of these can proceed in an open source
fashion by scientists around the world. At the same time, it is
recognized that there is often a strong overlap between probes,
leads and drugs and that some of this work will have to operate
within the constraints that inevitably accompany pharmaceutical
research if patients with serious diseases are to benefit from
important new drugs.
The reality is that bad probes will bite the dust whereas better
probes will evolve, thrive and prosper until they too are replaced
by fitter and more powerful progeny—in a true Darwinian
process. Improving the speed and efficiency of probe evolution
will bring great benefits to basic, translational and drug discovery
research as we move forward into the second decade of exploit-
ing the human genome sequence.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and Supplemental Text and
can be found with this article online at doi:10.1016/j.chembiol.2010.05.013.
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